Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxxinity, Inc. - Class A Common Stock (NQ: VAXX )

0.1398 -0.0602 (-30.10%)
Streaming Delayed Price Updated: 3:17 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vaxxinity, Inc. - Class A Common Stock

< Previous 1 2 Next >
Vaxxinity Issues Shareholder Letter
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company’s clinical data in Parkinson’s disease 
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients 
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at Upcoming Investor Conferences in September
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Joins TransCelerate Research and Development Consortium
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference 
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at Upcoming Investor Conferences in November
From Vaxxinity, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.